written on 07.06.2016

PharmaBoardroom Releases New France Pharmaceuticals Report


Focus Reports releases its new 67 page France Healthcare and Life Sciences Report 2016.

This report offers companies, investors, policymakers, and stakeholders crucial insight into a country with a rich tradition in pharmaceuticals and healthcare that is now at the forefront of innovative new trends within these industries

The report features interviews with the global head of Ipsen, a representative of the IMS, and of the French pricing agency CEPS. Also included are interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the country’s healthcare and pharma sectors.

This report is an authoritative assessment of the French healthcare and pharma markets and covers:


We ask how France can continue to offer universal access to the latest innovations in the long-term

Market Access

With one of the highest rates of market access delay in Europe, we investigate how the French state aims to remedy this situation and how companies in France negotiate it


One of the hottest topics in pharma today; we look at how French players are using cutting edge technology and digital innovations to deliver better, cheaper, and quicker healthcare to patients


The report includes interviews with:

  • Dominique Giorgi, CEPS
  • Claude Le Pen, IMS Health
  • Marc de Garidel, Ipsen
  • Judith Greciet, Onxeo
  • Aurélien Chaufour, Anjac Health & Beauty
  • Patrick Winkler & Geoffrey Billon, Medpace
  • Yann Quentric, Iris Pharma


  • “To maintain the delicate balance between public benefit and pharmaceutical profits, there cannot be a company that sets prices that are much higher than the norm.”

Dominique Giorgi, CEPS

  • “Increasingly the private health system will enter the public domain. [Private health insurance] will no longer be seen as complementary but basic insurance.”

Claude Le Pen, IMS Health

  • “By 2016 [the US] will overtake France to become our number one affiliate.”

Marc de Garidel, Ipsen

  • “We have a historical French touch in the high quality of our people and machinery that remains attractive to this day.”

Aurélien Chaufour, Anjac Health & Beauty

  • “For complex trials concerning rare diseases and pediatric care, France has proven repeatedly to be an exemplary location.”

Patrick Winkler & Geoffrey Billon, Medpace

  • Establishing a common language among our administrative bodies would be an invaluable step in expediting…delays.”

Yann Quentric, Iris Pharma